Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKBANASDAQ:ANIXNASDAQ:PRPHNASDAQ:YMAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$2.92+2.1%$2.21$0.80▼$2.98$751.14M0.882.91 million shs3.96 million shsANIXAnixa Biosciences$2.50$2.71$2.07▼$4.20$80.49M0.4389,620 shs115,440 shsPRPHProPhase Labs$0.36+12.4%$0.33$0.22▼$5.36$14.96M-0.472.80 million shs1.63 million shsYMABY-mAbs Therapeutics$4.41+2.1%$4.39$3.55▼$16.11$199.70M0.53311,911 shs181,552 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics+2.10%0.00%+22.69%+62.22%+165.45%ANIXAnixa Biosciences0.00%-4.21%-9.42%-18.03%+3.31%PRPHProPhase Labs+12.36%+9.86%-2.41%-18.20%-92.87%YMABY-mAbs Therapeutics+2.08%+4.26%+7.56%-19.96%-63.91%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKBAAkebia Therapeutics4.1765 of 5 stars4.62.00.04.02.80.00.6ANIXAnixa Biosciences2.1088 of 5 stars3.63.00.00.02.21.70.0PRPHProPhase Labs1.9178 of 5 stars0.05.00.00.02.71.71.3YMABY-mAbs Therapeutics3.4713 of 5 stars4.41.00.00.03.14.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics 3.20Buy$6.63126.88% UpsideANIXAnixa Biosciences 3.25Buy$9.00260.00% UpsidePRPHProPhase Labs 0.00N/AN/AN/AYMABY-mAbs Therapeutics 2.82Moderate Buy$16.60276.42% UpsideCurrent Analyst Ratings BreakdownLatest YMAB, AKBA, ANIX, and PRPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025YMABY-mAbs TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $11.005/14/2025YMABY-mAbs TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $14.005/14/2025YMABY-mAbs TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$21.00 ➝ $20.004/28/2025AKBAAkebia TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025AKBAAkebia TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$7.004/22/2025YMABY-mAbs TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeNeutral ➝ Underperform$3.004/10/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/4/2025AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.50 ➝ $7.504/1/2025AKBAAkebia TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.003/26/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/25/2025ANIXAnixa BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$184.91M4.15N/AN/A($0.16) per share-18.25ANIXAnixa Biosciences$210K383.30N/AN/A$0.59 per share4.24PRPHProPhase Labs$5.85M2.56N/AN/A$2.74 per share0.13YMABY-mAbs Therapeutics$88.66M2.25N/AN/A$2.32 per share1.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$51.92M-$0.21N/AN/AN/A-27.07%N/A-20.57%8/14/2025 (Estimated)ANIXAnixa Biosciences-$12.55M-$0.39N/A∞N/AN/A-58.55%-53.29%6/3/2025 (Estimated)PRPHProPhase Labs-$16.78M-$1.26N/AN/AN/A-217.64%-62.92%-30.22%8/13/2025 (Estimated)YMABY-mAbs Therapeutics-$21.43M-$0.64N/AN/AN/A-28.22%-24.61%-18.49%8/11/2025 (Estimated)Latest YMAB, AKBA, ANIX, and PRPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/3/2025Q2 2025ANIXAnixa Biosciences-$0.10N/AN/AN/AN/AN/A5/20/2025Q1 2025PRPHProPhase Labs-$0.18-$0.12+$0.06$0.12$2.45 million$1.43 million5/13/2025Q1 2025YMABY-mAbs Therapeutics-$0.22-$0.12+$0.10-$0.12$19.97 million$20.90 million5/8/2025Q1 2025AKBAAkebia Therapeutics-$0.03$0.03+$0.06$0.03$44.88 million$57.34 million3/13/2025Q4 2024AKBAAkebia Therapeutics-$0.05-$0.10-$0.05-$0.10$37.36 million$46.50 million3/11/2025Q1 2025ANIXAnixa Biosciences-$0.10-$0.10N/A-$0.10N/AN/A3/4/2025Q4 2024YMABY-mAbs Therapeutics-$0.13-$0.15-$0.02-$0.15$26.70 million$26.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/AANIXAnixa BiosciencesN/AN/AN/AN/AN/APRPHProPhase LabsN/AN/AN/AN/AN/AYMABY-mAbs TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia TherapeuticsN/A1.521.21ANIXAnixa BiosciencesN/A8.548.54PRPHProPhase Labs0.481.471.33YMABY-mAbs TherapeuticsN/A3.923.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%ANIXAnixa Biosciences29.13%PRPHProPhase Labs9.45%YMABY-mAbs Therapeutics70.85%Insider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics3.00%ANIXAnixa Biosciences25.30%PRPHProPhase Labs20.70%YMABY-mAbs Therapeutics22.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics430262.64 million209.24 millionOptionableANIXAnixa Biosciences532.20 million24.05 millionOptionablePRPHProPhase Labs13041.54 million18.93 millionOptionableYMABY-mAbs Therapeutics15045.28 million34.71 millionOptionableYMAB, AKBA, ANIX, and PRPH HeadlinesRecent News About These CompaniesY-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025May 26 at 11:39 PM | insidermonkey.comY-mAbs Therapeutics Presents GD2-SADA Data at Advances in Neuroblastoma Research MeetingMay 26 at 10:34 AM | quiverquant.comY-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research MeetingMay 26 at 10:00 AM | globenewswire.comY-mAbs Therapeutics’ SWOT analysis: antibody innovator’s stock faces growth hurdlesMay 24, 2025 | investing.comHC Wainwright Brokers Decrease Earnings Estimates for YMABMay 23, 2025 | marketbeat.comHC Wainwright Brokers Reduce Earnings Estimates for YMABMay 23, 2025 | americanbankingnews.comFY2026 Earnings Forecast for YMAB Issued By HC WainwrightMay 22, 2025 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Price Target Cut to $11.00 by Analysts at HC WainwrightMay 21, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Has $4.82 Million Stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)May 20, 2025 | marketbeat.comHC Wainwright Cuts Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $11.00May 20, 2025 | americanbankingnews.comYMAB FY2025 EPS Forecast Raised by Cantor FitzgeraldMay 18, 2025 | americanbankingnews.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $16.70 Consensus Target Price from AnalystsMay 18, 2025 | americanbankingnews.comWedbush Cuts Earnings Estimates for Y-mAbs TherapeuticsMay 17, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Rating of "Moderate Buy" from BrokeragesMay 17, 2025 | marketbeat.comTruist Financial Sticks to Its Buy Rating for Y-Mabs Therapeutics (YMAB)May 16, 2025 | theglobeandmail.comParadigm Biocapital Advisors LP Grows Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)May 16, 2025 | marketbeat.comY-mAbs Therapeutics Inc (YMAB) Q1 2025 Earnings Call Highlights: Navigating Growth and ChallengesMay 14, 2025 | finance.yahoo.comY-mAbs Therapeutics, Inc.: Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate DevelopmentsMay 13, 2025 | finanznachrichten.deY-mAbs Therapeutics, Inc. (YMAB) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comY-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue EstimatesMay 13, 2025 | zacks.comY-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025May 13, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeYMAB, AKBA, ANIX, and PRPH Company DescriptionsAkebia Therapeutics NASDAQ:AKBA$2.92 +0.06 (+2.10%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$2.92 0.00 (-0.17%) As of 05/27/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Anixa Biosciences NASDAQ:ANIX$2.50 0.00 (0.00%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$2.52 +0.02 (+0.60%) As of 05/27/2025 06:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.ProPhase Labs NASDAQ:PRPH$0.36 +0.04 (+12.36%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$0.35 -0.01 (-2.78%) As of 05/27/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.Y-mAbs Therapeutics NASDAQ:YMAB$4.41 +0.09 (+2.08%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$4.41 0.00 (0.00%) As of 05/27/2025 05:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Apple Sinks After New 25% Tariff Announcement—What's The Bottom? MarketBeat Week in Review – 05/19 - 05/23 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.